Welcome to our dedicated page for Karyopharm Therapeutics SEC filings (Ticker: KPTI), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Karyopharm Therapeutics Inc. filings document the formal disclosures of a commercial-stage oncology company centered on XPOVIO (selinexor), clinical development programs, financing arrangements, and governance matters. Form 8-K reports include operating and financial results, preliminary revenue and liquidity disclosures, clinical and regulatory updates, material agreements, and capital-structure events.
The company’s SEC record also includes proxy materials for annual and special stockholder meetings, director elections, executive compensation, shareholder voting matters, and amendments to authorized share capacity. Additional filings describe private placements, common stock and warrant structures, sales under equity offering arrangements, and amendments to credit and guaranty agreements, including covenant and liquidity terms.
Karyopharm Therapeutics Inc. approved a new 2026 Leadership Cash Retention Program on July 13, 2026 for certain employees, including all named executive officers and the Chief Financial Officer. The program is intended to incentivize retention of key employees during a period in which the company is expecting several meaningful catalysts.
The program replaces previously guaranteed amounts under the company’s Annual Bonus Plan for 2026. Lump-sum cash retention awards will be paid as follows: Richard Paulson, President and CEO, $1,725,000; Stuart Poulton, EVP and Chief Development Officer, $640,000; Dr. Reshma Rangwala, EVP, Chief Medical Officer and Head of Research, $725,000; and Lori Macomber, EVP, Chief Financial Officer and Treasurer, $625,000.
Awards may be subject to repayment if employment ends for any reason other than by the company without cause, by the executive for good reason, or due to death or permanent disability, before the earlier of 12 months from the payment date or 30 days after a qualifying corporate event. Amounts paid under this program will reduce payments due under previously agreed severance arrangements.
THERAPEUTICS INC group T. Rowe Price Investment Management, Inc. filed an amended Schedule 13G/A reporting beneficial ownership of 1,539,147 shares, representing 6.6% of the outstanding common stock as disclosed in the filing. The filer reports sole power to vote and sole power to dispose over 786,135 shares. The filing is signed and dated 06/05/2026.
Karyopharm Therapeutics Inc. reported that stockholders approved an amendment to its 2022 Equity Incentive Plan, adding 3,000,000 shares of common stock for equity awards. Stockholders also increased shares available under the Amended & Restated 2013 Employee Stock Purchase Plan by 1,400,000 shares.
The Board’s Compensation Committee adopted a broad-based retention program using performance-based restricted stock units, covering an aggregate of 3,838,380 PSUs for eligible employees. Awards include 343,000 PSUs for each of two tranches to President and CEO Richard Paulson, with vesting tied to specified clinical and other milestones and continued service.
Stockholders elected two Class I directors, approved executive compensation on an advisory basis, and ratified Ernst & Young LLP as independent auditor for the fiscal year ending December 31, 2026.
Karyopharm Therapeutics Inc. director Christy J. Oliger received an equity award in the form of 15,508 shares of Common Stock, reported as a grant of restricted stock units (RSUs) with a price of $0.00 per share as compensation rather than a market purchase.
The award was made under the company’s 2022 Equity Incentive Plan. Each RSU converts into one share of common stock, vesting 100% on May 21, 2027. However, actual share delivery is deferred until the earlier of the director’s separation from service or a qualifying change-in-control event, so the economic benefit is realized over time.
Karyopharm Therapeutics Inc. director Deepika Pakianathan received an equity award in the form of 15,508 restricted stock units, which convert into common stock on a one-for-one basis. The RSUs vest in full on May 21, 2027, with share delivery deferred until separation from service or a change-in-control event.
Karyopharm Therapeutics Inc. director Chen Schor reported an award of 15,508 shares of common stock in the form of restricted stock units (RSUs) granted at no cash cost as director compensation.
The RSUs were granted under the 2022 Equity Incentive Plan and convert into common stock on a one-for-one basis. They vest 100% on May 21, 2027, with delivery of the underlying shares deferred until the earlier of Schor’s separation from service or a change-in-control event. The filing shows no open-market buying or selling, only a stock-based compensation grant resulting in direct ownership of 15,508 shares after the award.
Su Zhen reported acquisition or exercise transactions in this Form 4 filing.
Karyopharm Therapeutics Inc. director Su Zhen received a grant of 15,508 restricted stock units (RSUs) of common stock as equity compensation. The RSUs vest 100% on May 21, 2027, and delivery of the underlying shares is deferred until separation from service or a change-in-control event. Following this award, Su Zhen directly holds 15,508 shares/RSUs in total.
Karyopharm Therapeutics Inc. director Garen G. Bohlin received an award of 15,508 restricted stock units (RSUs) under the company’s 2022 Equity Incentive Plan. These RSUs will vest 100% on May 21, 2027 and convert into common stock on a one-for-one basis.
Delivery of the vested shares is deferred until the earlier of the director’s separation from service or a change-in-control event. Following this grant, Bohlin holds 18,517 shares of common stock. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics Inc. director Barry E. Greene reported an equity compensation grant. He received 15,508 restricted stock units (RSUs) of common stock at no cash cost under the company’s 2022 Equity Incentive Plan, as amended.
The RSUs convert into common stock on a one-for-one basis and vest 100% on May 21, 2027. Delivery of shares is deferred until the earlier of Greene’s separation from service or a change-in-control event. After this award, he holds 16,415 shares of common stock directly. All amounts reflect Karyopharm’s one-for-fifteen reverse stock split effected on February 25, 2025.
Karyopharm Therapeutics joint Schedule 13G filed by Ikarian Capital, LLC and Neil Shahrestani reports beneficial ownership of 5% or less of Common Stock (CUSIP 48576U205) as of 03/31/2026. The filing lists Ikarian Capital as investment manager to a fund and managed accounts and includes a Joint Filing Agreement signed on 05/15/2026.